Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:03:42 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



Q:ZLAB - ZAI LAB LIMITED ADS EACH REP 10 ORD SHS - http://www.zailaboratory.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ZLAB - Q0.116.92·19.750.519.40-0.53-2.7463.78,6744,84419.84  20.01  19.3137.92  13.4819:17:54May 1615 min RT 2¢

Recent Trades - Last 10 of 4844
Time ETExPriceChangeVolume
19:17:54Q19.50-0.43100
17:47:08Q19.60-0.33100
16:06:09Q19.30-0.631
16:00:05Q19.40-0.533,958
16:00:05Q19.40-0.53196
16:00:00Q19.40-0.53133
16:00:00Q19.40-0.53100
16:00:00Q19.40-0.5334
16:00:00Q19.40-0.53173
16:00:00Q19.40-0.53173

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-16 07:30U:ZLABNews ReleaseZai Lab Announces Participation in May and June Investor Conferences
2024-05-14 07:30U:ZLABNews ReleaseZai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
2024-05-12 20:20U:ZLABNews ReleaseZai Lab Announces Approval of AUGTYRO(TM) (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA
2024-05-08 16:05U:ZLABNews ReleaseZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
2024-04-15 07:30U:ZLABNews ReleaseZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
2024-04-11 07:30U:ZLABNews ReleaseZai Lab Statement on Executive Management Team's Agreement on Share Activities
2024-04-02 07:30U:ZLABNews ReleaseZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
2024-04-01 07:30U:ZLABNews ReleaseZai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
2024-03-27 09:29U:ZLABNews ReleaseZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
2024-03-13 19:05U:ZLABNews ReleaseZai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
2024-03-06 16:01U:ZLABNews ReleaseZai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
2024-03-06 07:30U:ZLABNews ReleaseZai Lab Announces Participation in March Investor Conference
2024-02-27 16:05U:ZLABNews ReleaseZai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
2024-01-25 16:15U:ZLABNews ReleaseZai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
2024-01-10 17:12U:ZLABNews ReleaseZai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
2023-12-19 07:30U:ZLABNews ReleaseZai Lab Announces Participation in January Investor Conference
2023-12-13 08:53U:ZLABNews ReleaseParatek Pharmaceuticals Announces Inclusion of Oral NUZYRA ‚ ® in China ¢ € ™s National Reimbursement Drug List
2023-12-12 23:10U:ZLABNews ReleaseZai Lab Announces the First Listing of VYVGART ‚ ® (efgartigimod alfa injection) and Other Updates in China ¢ € ™s National Reimbursement Drug List
2023-11-07 16:05U:ZLABNews ReleaseZai Lab Announces Third Quarter 2023 ‚  Financial Results and Recent Corporate Updates
2023-10-26 07:30U:ZLABNews ReleaseZai Lab Announces Participation in November Investor Conferences